Virax Biolabs Group (VRAX) Competitors $1.75 -0.14 (-7.41%) (As of 12/20/2024 05:40 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends VRAX vs. TENX, CTXR, FNCH, CGTX, CVKD, MIRA, UBX, CARM, PIRS, and APREShould you be buying Virax Biolabs Group stock or one of its competitors? The main competitors of Virax Biolabs Group include Tenax Therapeutics (TENX), Citius Pharmaceuticals (CTXR), Finch Therapeutics Group (FNCH), Cognition Therapeutics (CGTX), Cadrenal Therapeutics (CVKD), MIRA Pharmaceuticals (MIRA), Unity Biotechnology (UBX), Carisma Therapeutics (CARM), Pieris Pharmaceuticals (PIRS), and Aprea Therapeutics (APRE). These companies are all part of the "pharmaceutical products" industry. Virax Biolabs Group vs. Tenax Therapeutics Citius Pharmaceuticals Finch Therapeutics Group Cognition Therapeutics Cadrenal Therapeutics MIRA Pharmaceuticals Unity Biotechnology Carisma Therapeutics Pieris Pharmaceuticals Aprea Therapeutics Virax Biolabs Group (NASDAQ:VRAX) and Tenax Therapeutics (NASDAQ:TENX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, community ranking, institutional ownership, valuation, analyst recommendations, risk and media sentiment. Is VRAX or TENX more profitable? Virax Biolabs Group's return on equity of 0.00% beat Tenax Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Virax Biolabs GroupN/A N/A N/A Tenax Therapeutics N/A -46.00%-42.65% Does the media favor VRAX or TENX? In the previous week, Virax Biolabs Group had 1 more articles in the media than Tenax Therapeutics. MarketBeat recorded 2 mentions for Virax Biolabs Group and 1 mentions for Tenax Therapeutics. Virax Biolabs Group's average media sentiment score of 0.00 equaled Tenax Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Virax Biolabs Group 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tenax Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate VRAX or TENX? Tenax Therapeutics has a consensus target price of $16.00, indicating a potential upside of 185.20%. Given Tenax Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Tenax Therapeutics is more favorable than Virax Biolabs Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virax Biolabs Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Tenax Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Does the MarketBeat Community prefer VRAX or TENX? Tenax Therapeutics received 144 more outperform votes than Virax Biolabs Group when rated by MarketBeat users. CompanyUnderperformOutperformVirax Biolabs GroupN/AN/ATenax TherapeuticsOutperform Votes14456.03% Underperform Votes11343.97% Which has better valuation & earnings, VRAX or TENX? Virax Biolabs Group has higher revenue and earnings than Tenax Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVirax Biolabs Group$84.87K66.66-$6.73MN/AN/ATenax TherapeuticsN/AN/A-$7.71MN/AN/A Do institutionals & insiders believe in VRAX or TENX? 8.6% of Virax Biolabs Group shares are owned by institutional investors. Comparatively, 1.7% of Tenax Therapeutics shares are owned by institutional investors. 45.1% of Virax Biolabs Group shares are owned by company insiders. Comparatively, 3.7% of Tenax Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has more volatility & risk, VRAX or TENX? Virax Biolabs Group has a beta of 1.84, suggesting that its share price is 84% more volatile than the S&P 500. Comparatively, Tenax Therapeutics has a beta of 2.21, suggesting that its share price is 121% more volatile than the S&P 500. SummaryVirax Biolabs Group beats Tenax Therapeutics on 7 of the 13 factors compared between the two stocks. Ad Crypto 101 MediaTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW Get Virax Biolabs Group News Delivered to You Automatically Sign up to receive the latest news and ratings for VRAX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VRAX vs. The Competition Export to ExcelMetricVirax Biolabs GroupDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.66M$2.51B$5.14B$9.08BDividend YieldN/A0.73%5.09%4.23%P/E RatioN/A6.0790.1317.19Price / Sales66.6675.121,116.25117.05Price / CashN/A15.0543.1037.85Price / Book0.883.284.784.78Net Income-$6.73M$29.98M$120.31M$225.60M7 Day Performance11.46%-1.55%-1.92%-1.23%1 Month Performance-12.94%6.18%13.65%0.46%1 Year Performance32.58%-20.93%28.34%15.24% Virax Biolabs Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VRAXVirax Biolabs Group0.6841 of 5 stars$1.75-7.4%N/A+25.0%$5.66M$84,872.000.005News CoverageTENXTenax Therapeutics1.4549 of 5 stars$5.84-0.7%$16.00+174.0%-76.7%$19.91MN/A0.009News CoverageCTXRCitius Pharmaceuticals1.6536 of 5 stars$2.62-6.1%$100.00+3,716.8%-86.2%$18.94MN/A-0.4720FNCHFinch Therapeutics GroupN/A$11.75-2.1%N/A+251.4%$18.87M$110,000.00-1.36190News CoverageCGTXCognition Therapeutics2.8986 of 5 stars$0.45-5.6%$8.00+1,673.8%-62.9%$18.74MN/A-0.4920Analyst ForecastNews CoverageCVKDCadrenal Therapeutics1.7091 of 5 stars$11.00-1.8%$18.00+63.6%N/A$18.25MN/A-1.684News CoverageGap UpMIRAMIRA Pharmaceuticals2.6044 of 5 stars$1.10-1.8%$14.00+1,172.7%+0.5%$18.22MN/A-2.002Analyst RevisionNews CoverageUBXUnity Biotechnology3.0929 of 5 stars$1.08-3.6%$8.00+640.7%-42.5%$18.20M$240,000.00-0.8460Gap DownCARMCarisma Therapeutics3.5769 of 5 stars$0.43+6.3%$4.94+1,048.6%-85.6%$17.96M$20.27M-0.2620High Trading VolumePIRSPieris Pharmaceuticals1.2974 of 5 stars$13.60-15.7%N/A+9.7%$17.95M$42.81M-1.12140Gap DownAPREAprea Therapeutics3.2009 of 5 stars$3.26+1.9%$15.50+375.5%-19.9%$17.72M$580,000.00-1.147Analyst ForecastNews Coverage Related Companies and Tools Related Companies Tenax Therapeutics Competitors Citius Pharmaceuticals Competitors Finch Therapeutics Group Competitors Cognition Therapeutics Competitors Cadrenal Therapeutics Competitors MIRA Pharmaceuticals Competitors Unity Biotechnology Competitors Carisma Therapeutics Competitors Pieris Pharmaceuticals Competitors Aprea Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VRAX) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virax Biolabs Group Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Virax Biolabs Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VRAX Stock Alerts